PUMA BIOTECHNOLOGY, INC.

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of products for cancer care. Its primary commercial product is Nerlynx, an oral tablet formulation of neratinib used to treat specific forms of HER2-positive breast cancer. In addition, the company is developing alisertib, an in-licensed selective small-molecule inhibitor of Aurora Kinase A for potential use against lung and breast cancers. Puma Biotechnology serves healthcare providers and cancer patients requiring targeted oncology treatments.

The company maintains its principal executive offices in Los Angeles, California. In the United States, it markets its commercial drug through a direct specialty sales team of roughly 35 sales specialists. Globally, the company relies on third-party sub-license partners to handle regulatory filings and commercialization. Through these international partnerships, Nerlynx holds regulatory approvals in more than forty countries, including Canada, Australia, China, and member states of the European Union.

Summary of the business section of Puma Biotechnology's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, our workforce consisted of 179 full-time employees.”